• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助治疗后淋巴结降期在一组晚期宫颈癌患者中的作用。

The Role of Lymph Node Downstaging Following Neoadjuvant Treatment in a Group of Patients with Advanced Stage Cervical Cancer.

机构信息

Clinical Department No 10, General Surgery, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.

Department of Oncological Surgery, Oncological Institute "Prof. Dr. Alexandru Trestioreanu", 022328 Bucharest, Romania.

出版信息

Medicina (Kaunas). 2024 May 26;60(6):871. doi: 10.3390/medicina60060871.

DOI:10.3390/medicina60060871
PMID:38929488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11205351/
Abstract

: Cervical cancer is the fourth most frequent type of neoplasia in women. It is most commonly caused by the persistent infection with high-risk strands of human papillomavirus (hrHPV). Its incidence increases rapidly from age 25 when routine HPV screening starts and then decreases at the age of 45. This reflects both the diagnosis of prevalent cases at first-time screening and the likely peak of HPV exposure in early adulthood. For early stages, the treatment offers the possibility of fertility preservation.. However, in more advanced stages, the treatment is restricted to concomitant chemo-radiotherapy, combined, in very selected cases with surgical intervention. After the neoadjuvant treatment, an imagistic re-evaluation of the patients is carried out to analyze if the stage of the disease remained the same or suffered a downstaging. Lymph node downstaging following neoadjuvant treatment is regarded as an indubitable prognostic factor for predicting disease recurrence and survival in patients with advanced cervical cancer. This study aims to ascertain the important survival role of radiotherapy in the downstaging of the disease and of lymphadenectomy in the control of lymph node invasion for patients with advanced-stage cervical cancer. : We describe the outcome of patients with cervical cancer in stage IIIC1 FIGO treated at Bucharest Oncological Institute. All patients received radiotherapy and two-thirds received concomitant chemotherapy. A surgical intervention consisting of type C radical hysterectomy with radical pelvic lymphadenectomy was performed six to eight weeks after the end of the neoadjuvant treatment. : The McNemar test demonstrated the regression of lymphadenopathies after neoadjuvant treatment-: <0.001. However, the persistence of adenopathies was not related to the dose of irradiation (: 0.61), the number of sessions of radiotherapy (: 0.80), or the chemotherapy (: 0.44). Also, there were no significant differences between the adenopathies reported by imagistic methods and those identified during surgical intervention-: 0.62. The overall survival evaluated using Kaplan-Meier curves is dependent on the post-radiotherapy FIGO stage-: 0.002 and on the lymph node status evaluated during surgical intervention-: 0.04. The risk factors associated with an increased risk of death were represented by a low preoperative hemoglobin level (: 0.003) and by the advanced FIGO stage determined during surgical intervention (-value: 0.006 for stage IIIA and 0.01 for stage IIIC1). In the multivariate Cox model, the independent predictor of survival was the preoperative hemoglobin level (: 0.004, HR 0.535, CI: 0.347 to 0.823). Out of a total of 33 patients with neoadjuvant treatment, 22 survived until the end of the study, all 33 responded to the treatment in varying degrees, but in 3 of them, tumor cells were found in the lymph nodes during the intraoperative histopathological examination. : For advanced cervical cancer patients, radical surgery after neoadjuvant treatment may be associated with a better survival rate. Further research is needed to identify all the causes that lead to the persistence of adenopathies in certain patients, to decrease the FIGO stage after surgical intervention, and, therefore, to lower the risk of death. Also, it is mandatory to correctly evaluate and treat the anemia, as it seems to be an independent predictor factor for mortality.

摘要

宫颈癌是女性第四大常见的肿瘤类型。它通常由高危型人乳头瘤病毒(HPV)持续感染引起。从 25 岁开始进行常规 HPV 筛查时,其发病率迅速上升,然后在 45 岁时下降。这既反映了首次筛查时普遍病例的诊断,也反映了 HPV 在成年早期暴露的可能高峰。对于早期阶段,治疗提供了保留生育能力的可能性。然而,在更晚期,治疗仅限于联合化疗放疗,在非常选定的情况下,结合手术干预。新辅助治疗后,对患者进行影像学重新评估,以分析疾病的阶段是否保持不变或是否出现降级。新辅助治疗后淋巴结降级被认为是预测晚期宫颈癌患者疾病复发和生存的明确预后因素。本研究旨在确定放疗在疾病降级和淋巴结切除术在控制晚期宫颈癌淋巴结侵犯方面的重要生存作用。

我们描述了布加勒斯特肿瘤研究所治疗的 IIIC1FIGO 期宫颈癌患者的结局。所有患者均接受放疗,三分之二的患者接受了同期化疗。在新辅助治疗结束后六至八周,进行包括 C 型根治性子宫切除术和根治性盆腔淋巴结切除术的手术干预。

McNemar 检验显示新辅助治疗后淋巴结病消退:<0.001。然而,淋巴结病的持续存在与照射剂量无关(:0.61),放疗次数(:0.80)或化疗(:0.44)无关。此外,影像学方法报告的淋巴结病与手术干预中识别的淋巴结病之间没有显著差异:0.62。使用 Kaplan-Meier 曲线评估的总生存率取决于放疗后的 FIGO 分期:0.002 和手术干预期间评估的淋巴结状态:0.04。与死亡风险增加相关的危险因素包括术前血红蛋白水平低(:0.003)和术中确定的高级 FIGO 分期(-值:III 期 A 为 0.006,IIIC1 期为 0.01)。在多变量 Cox 模型中,生存的独立预测因素是术前血红蛋白水平(:0.004,HR 0.535,CI:0.347 至 0.823)。在总共 33 名接受新辅助治疗的患者中,有 22 名患者存活至研究结束,所有 33 名患者均在不同程度上对治疗有反应,但其中 3 名患者在术中组织病理学检查中发现淋巴结中有肿瘤细胞。

对于晚期宫颈癌患者,新辅助治疗后行根治性手术可能与生存率的提高相关。需要进一步研究以确定导致某些患者淋巴结病持续存在的所有原因,降低手术干预后的 FIGO 分期,从而降低死亡风险。此外,必须正确评估和治疗贫血,因为它似乎是死亡率的独立预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/fa5333250254/medicina-60-00871-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/f0aca43af531/medicina-60-00871-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/eac4d6db4a17/medicina-60-00871-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/0b456d6fab24/medicina-60-00871-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/4482199af979/medicina-60-00871-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/fa5333250254/medicina-60-00871-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/f0aca43af531/medicina-60-00871-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/eac4d6db4a17/medicina-60-00871-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/0b456d6fab24/medicina-60-00871-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/4482199af979/medicina-60-00871-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d2/11205351/fa5333250254/medicina-60-00871-g005.jpg

相似文献

1
The Role of Lymph Node Downstaging Following Neoadjuvant Treatment in a Group of Patients with Advanced Stage Cervical Cancer.新辅助治疗后淋巴结降期在一组晚期宫颈癌患者中的作用。
Medicina (Kaunas). 2024 May 26;60(6):871. doi: 10.3390/medicina60060871.
2
The Impact of Patient Characteristics, Risk Factors, and Surgical Intervention on Survival in a Cohort of Patients Undergoing Neoadjuvant Treatment for Cervical Cancer.患者特征、风险因素和手术干预对接受宫颈癌新辅助治疗的患者队列生存的影响。
Medicina (Kaunas). 2023 Dec 11;59(12):2147. doi: 10.3390/medicina59122147.
3
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
4
Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer.宫颈癌腹膜外淋巴结清扫术后患者的评估
Gynecol Oncol. 2005 Mar;96(3):658-64. doi: 10.1016/j.ygyno.2004.08.053.
5
Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer.淋巴疾病负担预测 2018 年FIGO 分期ⅡICp 宫颈癌辅助放化疗疗效。
Int J Gynecol Cancer. 2019 Nov;29(9):1355-1360. doi: 10.1136/ijgc-2019-000669. Epub 2019 Aug 17.
6
Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy.影响根治性子宫切除术和盆腔淋巴结清扫术治疗的ⅠB-ⅡB期宫颈癌预后因素的分析
Am J Clin Oncol. 2016 Dec;39(6):604-608. doi: 10.1097/COC.0000000000000100.
7
Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.国际妇产科联盟(FIGO)IB期无淋巴结转移宫颈癌的预后因素及根治性子宫切除术后辅助放疗的作用
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):286-92. doi: 10.1111/j.1048-891X.2004.014212.x.
8
Radical vaginal hysterectomy with extraperitoneal pelvic lymphadenectomy in cervical cancer.宫颈癌根治性经阴道子宫切除术联合腹膜外盆腔淋巴结清扫术
Eur J Gynaecol Oncol. 2001;22(1):31-5.
9
Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone.淋巴结转移的高危早期宫颈癌术后放疗的人群趋势和结局:同期放化疗与单纯放疗比较。
Am J Obstet Gynecol. 2020 May;222(5):484.e1-484.e15. doi: 10.1016/j.ajog.2019.10.010. Epub 2019 Oct 31.
10
[Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].[I a2-II a2期宫颈癌腹腔镜与开腹根治性子宫切除术后的长期肿瘤学结局:一项配对队列研究]
Zhonghua Fu Chan Ke Za Zhi. 2015 Dec;50(12):894-901.

本文引用的文献

1
The Impact of Patient Characteristics, Risk Factors, and Surgical Intervention on Survival in a Cohort of Patients Undergoing Neoadjuvant Treatment for Cervical Cancer.患者特征、风险因素和手术干预对接受宫颈癌新辅助治疗的患者队列生存的影响。
Medicina (Kaunas). 2023 Dec 11;59(12):2147. doi: 10.3390/medicina59122147.
2
Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: Retrospective Single-Center Study.新辅助化疗联合根治性手术治疗局部晚期宫颈癌:回顾性单中心研究
Cancers (Basel). 2023 Oct 29;15(21):5207. doi: 10.3390/cancers15215207.
3
Advances in Targeted Therapy for the Treatment of Cervical Cancer.
宫颈癌靶向治疗的进展
J Clin Med. 2023 Sep 15;12(18):5992. doi: 10.3390/jcm12185992.
4
Current Therapeutic Approaches in Cervical Cancer Based on the Stage of the Disease: Is There Room for Improvement?基于疾病分期的宫颈癌当前治疗方法:是否有改进的空间?
Medicina (Kaunas). 2023 Jun 30;59(7):1229. doi: 10.3390/medicina59071229.
5
Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: Can One Still Effectively Become a Mother? A Systematic Review of Fertility Outcomes.早期宫颈癌(≥2 厘米)的保留生育功能治疗:是否仍能有效地成为母亲?生育结局的系统评价。
Ann Surg Oncol. 2023 Sep;30(9):5587-5596. doi: 10.1245/s10434-023-13542-z. Epub 2023 Jun 1.
6
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023.ESGO/ESTRO/ESP 宫颈癌管理指南-2023 年更新版。
Int J Gynecol Cancer. 2023 May 1;33(5):649-666. doi: 10.1136/ijgc-2023-004429.
7
The recent natural history of human papillomavirus cervical infection in women living with HIV: A scoping review of meta-analyses and systematic reviews and the construction of a hypothetical model.人乳头瘤病毒(HPV)宫颈感染在 HIV 感染者中的近期自然史:对荟萃分析和系统评价的范围综述,以及构建一个假设模型。
HIV Med. 2023 Aug;24(8):877-892. doi: 10.1111/hiv.13490. Epub 2023 Apr 16.
8
Editorial: Methods in gynecological oncology.社论:妇科肿瘤学中的方法
Front Oncol. 2023 Mar 9;13:1167088. doi: 10.3389/fonc.2023.1167088. eCollection 2023.
9
Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer.975例2009年国际妇产科联盟(FIGO)IA-IIA期宫颈癌患者的淋巴结转移及危险因素分析
Gynecol Obstet Invest. 2023;88(1):30-36. doi: 10.1159/000527712. Epub 2022 Nov 30.
10
The Oncological Implication of Sentinel Lymph Node in Early Cervical Cancer: A Meta-Analysis of Oncological Outcomes and Type of Recurrences.前哨淋巴结在早期宫颈癌中的肿瘤学意义:肿瘤学结局和复发类型的荟萃分析。
Medicina (Kaunas). 2022 Oct 27;58(11):1539. doi: 10.3390/medicina58111539.